StockVS

Progyny, Inc. (PGNY) Analyse boursière

Santé

Progyny, Inc.

$25.05

+$0.17 (+0.68%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Progyny, Inc. (PGNY) operates as a benefits management entity that delivers specialized fertility, family building, and women's health benefits solutions throughout the United States. The company's core offering encompasses differentiated benefits plan design, including smart cycle treatment bundles, alongside personalized concierge-style services for clients within the healthcare sector. This entity functions specifically within the Healthcare sector, targeting the sub-industry of Healthcare Plans, which positions it to serve employers and individuals seeking reproductive and women-centric wellness coverage. With a market capitalization of $1.39 billion and an annual revenue of $1.29 billion supported by a workforce of 835 employees, the company demonstrates a significant scale within its niche. These financial figures indicate that Progyny has established a substantial operational footprint, suggesting it commands a meaningful share of the managed benefits market while maintaining a valuation that reflects its growth potential and specialized service model.

Santé financière

The company reported a trailing twelve-month revenue of $1.29 billion and generated a net income of $58.52 million, resulting in an EBITDA of $97.92 million. The substantial gap between the $1.29 billion in revenue and the $58.52 million in net income reveals a cost structure where operational expenses, including cost of goods sold and administrative costs, absorb approximately 95.4% of total revenue before interest and taxes. Free cash flow stands at $212.50 million, a figure that signifies strong financial flexibility and the ability to fund internal projects, repay obligations, or acquire other assets without relying heavily on external financing. Profitability metrics show a gross margin of 23.6%, an operating margin of 7.2%, and a profit margin of 4.5%, indicating that while the company generates revenue efficiently, a significant portion is consumed by operating costs before reaching the bottom line. The balance sheet is characterized by $310.10 million in cash holdings against $27.73 million in debt, supported by a debt-to-equity ratio of 5.37 which measures leverage relative to shareholders' equity. Despite the debt-to-equity figure, the liquidity position is robust as evidenced by a current ratio of 2.73, indicating that current assets are 2.73 times greater than current liabilities, ensuring ample short-term liquidity to meet obligations. Return on equity is reported at 12.5% while return on assets sits at 8.6%, metrics that reveal management's effectiveness in generating returns on the capital invested by shareholders and in utilizing the asset base to produce earnings.

Évaluation de la valorisation

The valuation metrics display a trailing P/E ratio of 26.05 and a forward P/E of 8.06, implying that the market expects a significant expansion in earnings over the coming year relative to current levels. The price-to-book ratio is recorded at 2.71, suggesting that the market values the company at a premium of 171% over its tangible book value. Alternative valuation measures include a price-to-sales ratio of 1.08 and an EV/EBITDA of 11.28, which provide context on how the company is valued relative to its sales volume and enterprise earnings before interest, taxes, depreciation, and amortization. Historical price volatility is contextualized by a 52-week high of $28.75 and a 52-week low of $16.28, where the current trading price sits at a specific point within this range reflecting recent market sentiment. The stock exhibits a beta of 0.99, indicating that its price volatility moves in tandem with the broader market, neither significantly amplifying nor dampening risk compared to the overall index.

Growth & Income

Revenue growth over the last year stands at 6.7%, while earnings growth has accelerated to 20.6%, demonstrating that profitability is expanding at a rate substantially faster than top-line sales. This divergence suggests improving operational leverage or cost efficiencies that are allowing net income to outpace revenue expansion. The company does not distribute a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all earnings are retained within the business to fund operations, growth initiatives, or balance sheet strengthening rather than being distributed to shareholders. Consequently, the overall growth and income profile is defined by capital retention and internal reinvestment rather than current income generation through dividends.

Comparaison avec les pairs

Progyny, Inc. (PGNY) opère dans le secteur Plans de Santé. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Progyny, Inc. PGNY $1.95B 32.3
UnitedHealth Group Incorporated UNH $342.24B 28.4
CVS Health Corporation CVS $115.76B 39.8
Elevance Health, Inc. ELV $84.23B 16.4

Le ratio P/E moyen du secteur Plans de Santé est de 45.1x. Progyny, Inc. se négocie à un P/E de 32.3.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Progyny, Inc.

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$1.95B
Ratio P/E
32.31
Plus Haut 52 Sem.
$28.75
Plus Bas 52 Sem.
$16.10
Volume Moyen
1.64M
Bêta
0.91

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
United States
Employés
835